Proud to Partner With:
Industry Partner:
Revolo Bio are advancing therapies that restore immune homeostasis, targeting the immune system upstream. They offer a unique mechanism through impact on both the regulatory and effector arms. On the regulatory side, they upregulate T and B regulatory cells. On the effector side, they downregulate effector T cells. This upstream, disease-agnostic and dual action approach results in a rapid and prolonged effect without broad immune suppression. They also have potential to offer dosing optionality through subcutaneous and sublingual routes, based on preclinical research, offering a highly competitive profile with potential to disrupt the current treatment landscape as
potential first line therapies.
Industry Partner:
Barinthus Bio is an emerging leader in the research and development of antigen-specific immunotherapies that guide T cells to fight disease. We are building on a rich history of cutting-edge innovations by our scientific founders from leading institutions. Barinthus Bio arose from the merger of Oxford University spinout Vaccitech, Plc and National Institutes of Health (NIH) and Johns Hopkins University spinout, Avidea Technologies, Inc. in 2021. Joining two leading immunotherapeutics companies with complementary technologies and expertisehas created powerful synergies, fueling innovation and a focused pipeline of promising product
candidates.
Industry Partner:
Industry Partner:
Industry Partner:
COUR Pharma is a clinical-stage biotechnology company developing therapies to treat patients with autoimmune diseases. COUR’s first-in-class therapies are based on our proprietary antigen-specific immune tolerance platform and are designed to reprogram the immune system to address the underlying root cause of immune-mediated diseases. Data from multiple clinical and preclinical programs have demonstrated the ability of COUR’s product candidates to induce antigen-specific immune tolerance and have the potential to treat a wide range of autoimmune diseases including Primary Biliary Cholangitis, Type 1 Diabetes and Myasthenia Gravis.
Exhibition Partner:
Miltenyi Biotec is a global leader innovating technologies and services for patient-specific cell and gene therapies, turning scientific discoveries into practical treatments for personalized medicine. Having pioneered a groundbreaking method of cell separation, Miltenyi Biotec continues to sets industry standards today. With over 35 years of expertise, it supports customers in biomedical discoveries, translating them into clinical applications to enable access to new therapies for patients. Miltenyi Biotec focuses on providing integrated, advanced solutions to address complex challenges in the treatment of cancers, autoimmune diseases, and inherited disorders. Through its Miltenyi Bioindustry division, it provides expert guidance to therapy developers, helping them efficiently and cost-effectively navigate the path from process development to commercialization. Miltenyi Biotec is headquartered in Bergisch Gladbach and has a global team of 4,900 employees across 24 countries.
Innovation Partner:
Infinity Bio leverages an antigen display technology for antibody reactome profiling and comprehensively measures the repertoire of reactivities against the entire human proteome or virome. Identifying pre-existing or de-novo (auto) antibody reactivities could reveal novel biomarkers of disease and clinical outcomes.
